233 related articles for article (PubMed ID: 31229161)
1. Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies.
Ng SY; Jacobsen ED
Hematol Oncol Clin North Am; 2019 Aug; 33(4):657-668. PubMed ID: 31229161
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
5. From empiric to mechanism-based therapy for peripheral T cell lymphoma.
Intlekofer AM; Younes A
Int J Hematol; 2014 Mar; 99(3):249-62. PubMed ID: 24510453
[TBL] [Abstract][Full Text] [Related]
6. Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E; Ruan J
J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
8. ECHELON-2 - brentuximab raises PTCL outcomes to new levels.
Killock D
Nat Rev Clin Oncol; 2019 Mar; 16(3):145. PubMed ID: 30602757
[No Abstract] [Full Text] [Related]
9. Therapeutic options in peripheral T cell lymphoma.
Zhang Y; Xu W; Liu H; Li J
J Hematol Oncol; 2016 Apr; 9():37. PubMed ID: 27071634
[TBL] [Abstract][Full Text] [Related]
10. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas.
Burton JS; Foley NC; Mehta-Shah N
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):65-76. PubMed ID: 37973458
[TBL] [Abstract][Full Text] [Related]
11. Emerging strategies in peripheral T-cell lymphoma.
Mehta-Shah N
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):41-46. PubMed ID: 31808829
[TBL] [Abstract][Full Text] [Related]
12. [Present and future perspective of the treatment of peripheral T-cell lymphoma].
Nagai H
Rinsho Ketsueki; 2020; 61(9):1259-1265. PubMed ID: 33162524
[TBL] [Abstract][Full Text] [Related]
13. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
Gisselbrecht C; Sibon D
Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
[TBL] [Abstract][Full Text] [Related]
14. Current management of peripheral T-cell lymphomas.
Gooptu M; Rhoades R; Pro B
Cancer Treat Res; 2015; 165():289-303. PubMed ID: 25655615
[TBL] [Abstract][Full Text] [Related]
15. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
16. T cell lymphoma: time to make discoveries and advance treatment.
Ishitsuka K
Int J Hematol; 2023 Apr; 117(4):473-474. PubMed ID: 36918503
[TBL] [Abstract][Full Text] [Related]
17. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.
Rodríguez J; Gutiérrez A; Martínez-Delgado B; Perez-Manga G
Crit Rev Oncol Hematol; 2009 Sep; 71(3):181-98. PubMed ID: 19056295
[TBL] [Abstract][Full Text] [Related]
18. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Marchi E; Raufi AG; O'Connor OA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
[TBL] [Abstract][Full Text] [Related]
19. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]